Artico
Marco Artico, Parabiago (mi) IT
Patent application number | Description | Published |
---|---|---|
20100029987 | Crystalline Form of Rasagiline and Process for the Preparation Thereof - A process for the preparation of (R)—N-propargyl-1-aminoindane, or a salt thereof, comprising reacting 1-indanone with propargylamine, in presence of a mixture of sodium borohydride and acetic acid, to obtain N-propargyl-1-aminoindane; and its conversion into (R)—N-propargyl-1-aminoindane or a salt thereof. | 02-04-2010 |
20100228034 | PROCESS FOR THE PREPARATION OF KETO INTERMEDIATES - Process for the preparation of 4-[1-oxo-4-[4-(hydroxyphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethylbenzenacetic acid, which is an intermediate useful in the preparation of fexofenadine, by hydrating asymmetric alkynes. | 09-09-2010 |
20120149772 | PROCESS FOR THE PREPARATION OF FESOTERODINE OR A SALT THEREOF - A process for the preparation of (R)-2-(3-diisopropylamino-1-phenylpropyl)-4-(hydroxymethyl)-phenol isobutyrate (Fesoterodine) or a pharmaceutically acceptable salt thereof having low content in impurities. | 06-14-2012 |
20120165525 | PROCESS FOR THE PREPARATION OF LINAGLIPTIN - The present invention relates to processes for the preparation of 8-(3R)-3-aminopiperidinyl)-7-butyn-2-yl-3 -methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione and novel intermediates useful in its synthesis. | 06-28-2012 |
20140163252 | PROCESS FOR THE PREPARATION OF AN ANTICONVULSANT COMPOUND - The invention provides a novel method for the preparation of intermediates useful in a process designed to obtain known 1,2,4-triaminobenzene compounds, and in particular a specific compound thereof having known anticonvulsant activity. Unlike known methods, the novel method does not require advance protection of the amino groups present on the substrate. | 06-12-2014 |
20140275610 | PROCESS FOR THE PREPARATION OF FESOTERODINE OR A SALT THEREOF - A process for the preparation of (R)-2-(3-diisopropylamino-1-phenylpropyl)-4-(hydroxymethyl)-phenol isobutyrate (Fesoterodine) or a pharmaceutically acceptable salt thereof having low content in impurities. | 09-18-2014 |
Marco Artico, Parabiago IT
Patent application number | Description | Published |
---|---|---|
20110152367 | PROCESS FOR THE PREPARATION OF FESOTERODINE WITH LOW IMPURITIES CONTENT - Disclosed is a process for the preparation of (R)-2-(3-diisopropylamino-1-phenylpropyl)-4-(hydroxymethyl)-phenol isobutyrate (Fesoterodine) or a pharmaceutically acceptable salt thereof having a low content of impurities such as tolterodine and tolterodine isobutyrate. | 06-23-2011 |
20110196123 | PROCESS FOR THE PREPARATION OF POLY-alpha-GLUTAMIC ACID AND DERIVATIVES THEREOF - The invention relates to an improved process for the preparation of poly-α-glutamic acids which comprises the polymerization of tertiary γ-esters of α-glutamic acid N-carboxy anhydride with appropriate solvents and initiators, followed by acid hydrolysis of the resulting poly-α-glutamic acid-γ-ester. The process is particularly advantageous in that it allows one to carefully control the molecular weight of the resulting poly-α-glutamic acid. The invention also relates to poly-α-glutamic acids capped at the amino terminus with carboxylic acids or amino acids and to a process for the preparation thereof. | 08-11-2011 |
Marco Artico, Baranzate (mi) IT
Patent application number | Description | Published |
---|---|---|
20140309437 | PROCESS FOR THE PREPARATION OF PHARMACEUTICAL INTERMEDIATES - Process for the preparation of intermediates that are useful in the synthesis of active pharmaceutical ingredients (API), in particular active in the central nervous system. | 10-16-2014 |
Roberta Artico, Milano IT
Patent application number | Description | Published |
---|---|---|
20120039953 | RILUZOLE AQUEOUS SUSPENSIONS - Physically and chemically stable aqueous suspensions of riluzole are disclosed together with the manufacturing methods thereof. Such aqueous suspensions comprise riluzole in particle form and at least a wetting agent, preferably a surfactant. Riluzole is in amounts from about 0.1% to about 20% w/v and has an average particle size lower than 200 μm; such suspensions are devoid of the known local (mouth) anaesthetic effects of riluzole. | 02-16-2012 |